Partner Kim Ashby was quoted in an Orlando Sentinel article, “Building Owners Weigh Preservation vs. Demolition,” covering how preserving downtown Orlando buildings ignites nearby neighborhoods in addition to keeping the buildings’ charm and character alive. The City of Orlando currently has multiple landmarks for sale, including the Church Street Exchange, Grand Avenue Elementary and the former Orlando Ballet building. The act of preserving buildings, or ‘adaptive reuse,’ instead of demolishing them is becoming increasingly popular in cities across the country.
After pointing out prior central Florida preservations including the former Orange County Courthouse’s renovation into a history museum and historical houses becoming Winter Park cultural venues, Ashby stated that “[preserving the buildings instead of demolishing them] not only repurposes the building; it repurposes the neighborhood and the whole community.”
Read the full article here.
After pointing out prior central Florida preservations including the former Orange County Courthouse’s renovation into a history museum and historical houses becoming Winter Park cultural venues, Ashby stated that “[preserving the buildings instead of demolishing them] not only repurposes the building; it repurposes the neighborhood and the whole community.”
Read the full article here.
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."